Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study

José Mordoh1,2,3, María Betina Pampena2, Mariana Aris2, Paula Alejandra Blanco2, Mónica Lombardo4, Erika María von Euw5, Soledad Mac Keon3, Michelle Yépez Crow2, Alicia Inés Bravo6, Juan Manuel O’Connor1, Ana Gabriela Orlando7,8, Franco Ramello9, Estrella Mariel Levy2 and María Marcela Barrio2*

1 Instituto Médico Especializado Alexander Fleming, Buenos Aires, Argentina, 2 Centro de Investigaciones Oncológicas-Fundación Cáncer, Buenos Aires, Argentina, 3 Fundación Instituto Leloir, IIBBA-CONICET, Buenos Aires, Argentina, 4 Nobeltri, Buenos Aires, Argentina, 5 UCLA JCCC-Translational Oncology Research Labs, Los Angeles, CA, United States, 6 Unidad de Immunopatología, Hospital Interzonal General de Agudos Eva Perón, San Martín, Argentina, 7 Hospital Central Olga Rizzi, Reconquista, Argentina, 8 Instituto Oncológico Mater Dei, Reconquista, Argentina, 9 Centro Médico San Lucas, Gualeguaychu, Argentina

The irradiated, allogeneic, cellular CSF-470 vaccine plus Bacillus Calmette–Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) is being tested against medium-dose IFN-α2b in stages IIB–III cutaneous melanoma (CM) patients (pts) after surgery in an open, randomized, Phase II/III study. We present the results of the Phase II part of the ongoing CASVAC-0401 study (ClinicalTrials.gov: NCT01729663). Thirty-one pts were randomized to the CSF-470 vaccine (n = 20) or to the IFN-α2b arm (n = 11). During the 2-year treatment, immunized pts should receive 13 vaccinations. On day 1 of each visit, 1.6 × 10^7 irradiated CSF-470 cells plus 10^6 colony-forming units BCG plus 100 µg rhGM-CSF were administered intradermally, followed

**Abbreviations:** Ab, antibodies; Ags, antigens; BCG, Bacillus Calmette–Guerin; CM, cutaneous melanoma; DCs, dendritic cells; DFS, disease-free survival; DMFS, distant metastasis-free survival; DTH, delayed-type hypersensitivity; FFPE, formalin-fixed, paraffin-embedded; F-UP, follow-up; HD, healthy donor; HLA, human leukocyte antigen; Igs, immunoglobulins; MAbs, monoclonal antibodies; MU, million units; NED, no evidence of disease; OS, overall survival; pts, patients; PBMC, peripheral blood mononuclear cells; PBS, phosphate saline buffer; PI, proliferative index; PRO, progressive disease; QOL, quality of life; rhGM-CSF, recombinant human granulocyte macrophage-colony stimulating factor.
INTRODUCTION

Despite recent advances in its treatment, cutaneous melanoma (CM), an immunogenic and highly mutated tumor (1, 2), continues to be a dreadful disease. The progressive acquisition of mutations in driver genes (3) confers survival advantage to melanoma cells, but at the same time creates foreign antigens (Ags), the so-called neoantigens or neoepitopes, which would render neoplastic cells detectable by the immune system and target them for destruction (4). Cancer immunotherapies include approaches ranging from stimulating immune effectors to countering inhibitory and suppressive mechanisms. Strategies to activate effector immune cells include vaccination with tumor Ags or augmentation of Ag presentation to increase the ability of the patient’s immune system to mount an immune response against neoplastic cells (5). Targeting the immune checkpoints CTLA-4 and PD-1 with monoclonal antibodies (MAbs) aim to release natural breaks that control immune function in physiological situations, to increase and sustain antitumor immune responses, either to shared tumor Ags (i.e., cancer testis Ags) and/or to neoantigens (6). However, although cancer immunotherapy is currently brighter than ever before, the outcome of most patients (pts) remains dismal. The mechanism of action of anti-PD-1 and anti-CTLA-4 MAbs is to release inhibition on CD4 or CD8 T lymphocytes, which recognize tumor-derived peptides restrictively presented in the context of human leukocyte antigen (HLA) molecules. This approach, however, leaves HLA-negative tumor cells unattended, and it has been known for long that HLA downexpression is an escape mechanism for tumor cells (7, 8). To increase the chances of longer survival and even cure, great attention is being focused on adjuvant treatments to pts who, after elimination of macroscopic disease with surgery, might still lodge microscopic tumor foci with a high degree of biological heterogeneity. Present treatment at the adjuvant setting is unsatisfactory. Adjuvant IFN-α2b increases disease-free survival (DFS) but not overall survival (OS); it is accompanied with considerable toxicity (9, 10); and is not universally considered as a gold standard treatment (11). Besides, the optimal dose and duration of IFN-α2b treatment are still unclear (12, 13). A report of the long-term results of the randomized Phase III Trial EORTC 18991 of adjuvant therapy with pegylated-IFN-α2b vs observation in resected stage III CM also concluded that no significant increase in distant metastasis-free survival (DMFS) or OS was noted in the overall population, although some benefit was found in pts with ulcerated tumors (10). Also, adjuvant treatment with ipilimumab has yielded similar results to IFN-α2b, increasing DFS at the expense of considerable immune-related toxicities (14), and a Phase III study comparing both treatments is underway (ECOG 1609). Another randomized study (SWOG S1404) is also currently comparing high-dose IFN-α2b to pembrolizumab in pts at high risk for recurrence and death after surgery (15). Very recently, a Phase III trial (EORTC 18071) of ipilimumab as adjuvant therapy for high-risk stage III melanoma pts, at a dose of 10 mg/kg for 3 years resulted in a significantly higher rate of 5-year recurrence-free survival (40.8%), DMFS (48.3%), and OS (65.4%) than placebo (30.3%, 38.9%, and 54.4% respectively). However, the rate of immune-related toxicities with ipilimumab was substantial and led to the discontinuation of treatment in ~40% of the pts (16).

In this scenario, active immunization with vaccines can be revisited as an interesting treatment, particularly in the adjuvant setting. The interest in cancer vaccination has emerged from the results of several clinical studies demonstrating that vaccines could improve clinical outcome of immunotherapy protocols. Among them we can mention the addition of a peptide vaccine to high-dose interleukin-2 (IL-2) (17), the use of a GM-CSF secreting tumor vaccine in combination with CTLA-4 blockade for metastatic prostate cancer (18), and the use of an autologous vaccine plus Bacillus Calmette–Guerin (BCG) that showed an increased response rate with subsequent ipilimumab for progressive disease in stage III melanoma pts (19). The experience acquired in recent years led to the increasing understanding that on days 2–4 by 100 μg rhGM-CSF. IFN-α2b pts should receive 10 million units (MU)/day/5 days a week for 4 weeks; then 5 MU thrice weekly for 23 months. Toxicity and quality of life (QOL) were evaluated at each visit. With a mean and a maximum follow-up of 39.4 and 83 months, respectively, a significant benefit in the distant metastasis-free survival (DMFS) for CSF-470 was observed (p = 0.022). Immune monitoring showed an increase in antitumoral cellular and humoral response in vaccinated pts. CSF-470 was well tolerated; 20/20 pts presented grades 1–2 dermic reactions at the vaccination site; 3/20 pts presented grade 3 allergic reactions. Other adverse events (AEs) were grade 1. Pts in the IFN-α2b arm presented grades 2–3 hematological (7/11), hepatic (2/11), and cardiac (1/11) toxicity; AEs in 9/11 pts forced treatment interruptions. QOL was significantly superior in the vaccine arm (p < 0.0001). Our results suggest that CSF-470 vaccine plus BCG plus GM-CSF can significantly prolong, with lower toxicity, the DMFS of high-risk CM pts with respect to medium-dose IFN-α2b. The continuation of a Phase III part of the CASVAC-0401 study is encouraged.

Keywords: cutaneous melanoma, CSF-470 allogeneic cell vaccine, Bacillus Calmette–Guerin, rhGM-CSF, IFN-α2b, Phase II clinical study
cancer immunotherapy is a multifaceted strategy and that combination modalities should be more efficient to prevent disease recurrence.

With the aim of inducing adaptive and innate immune responses against micrometastatic foci, targeting both HLA-positive and HLA-negative tumor cells, we developed the CSF-470 vaccine (Vaccimel), an inert scaffold of four lethally irradiated allogeneic CM cell lines, co-adjuvated with BCG and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF). The rationale of such combination is: (i) to use a cytokine-treated, irradiated allogeneic vaccine to challenge the immune system with a broad repertoire of CM Ags (20) and with non-identical HLA to trigger host-vs-graft reaction; (ii) to use BCG in every vaccination to induce local inflammation, to polarize immune cells toward a Th1 response, and to activate NK cells cytotoxicity and memory-like response (21, 22); (iii) to inject rhGM-CSF with every vaccination, since at low doses this cytokine is a strong monocyte attractant (23, 24), and it is essential to differentiate monocytes into dendritic cells (DCs) (25). It could thus be assumed that this combination should favor Ag uptake by macrophages and DC and boost adaptive immunity through Ag presentation to naïve lymphocytes, either locally or after migration to lymph nodes (26, 27). Besides, it should also increase the innate immunity response. Another Phase III clinical assay using irradiated allogeneic tumor cells (Canvaxin) plus BCG vs placebo with BCG was interrupted due to lack of efficacy. However, in that study, allogeneic cells were not pretreated with cytokines, BCG was only injected twice, and no GM-CSF was used (28).

In a previous Phase I study of Vaccimel plus BCG and escalating doses of rhGM-CSF on 20 pts with stages IIB–IV CM, it was found that 400 µg rhGM-CSF per vaccination divided into four daily doses was optimal (29). From that basis, the Phase II–III trial CASVAC-0401, in which stages IIB, IIC, and III CM pts were randomized to receive the CSF-470 vaccine plus BCG plus GM-CSF vs medium-dose IFN-α2b, was launched in 2009. The results corresponding to the end of the Phase II stage of this study are herein reported.

MATERIALS AND METHODS

CSF-470 Vaccine

The CSF-470 vaccine consists of 1.6 × 10⁷ lethally irradiated cells derived from four CM cell lines established in-house (30), MEL-X1, MEL-X2, MEL-X3, and MEL-XX4, which are deposited at the German Collection of Microorganisms and Cell Cultures (DSMZ), Braunschweig, Germany. All cell lines were established from metastatic CM tumors. Cells were cultured as previously described (30). The cell lines were grown in a GMP core facility at the Centro de Investigaciones Oncologicas-FUCA. For vaccine preparation, the four cell lines were thawed, washed, mixed, and subsequently irradiated at 70 Gy (Siemens Lineal Accelerator). The cells were frozen in vaccine doses (1.6 × 10⁷ total cells) in liquid nitrogen until use. For vaccine administration each dose was thawed, washed, and resuspended in Dulbecco’s Modified Eagle Medium.

RNASeq was performed for each cell line with the sequencing platform Illumina Hiseq 4000, with more than 20 M high-quality single-end reads per sample (BGI Americas). Quality control of reads was performed with FASTX-Toolkit (31) and FastQC (32). Reads were aligned to the latest human Hg38 reference genome using the STAR spliced read aligner (33). Fragment counts were derived using HTSeq package (34). Differentially expressed genes were identified by a ranking based on adjusted p-values ≤ 0.005 and a false discovery rate ≤ 0.1 using the R/Bioconductor package edgeR (35). In Figure 1A, we show the expression profile of several melanoma-associated Ags, selected from RNASeq data that have been previously shown to be immunogenic in CM pts (36). Also, vaccine cells express GD2 and GD3 gangliosides as detected by flow cytometry as previously described (37) (Figure 1B).

Study Design and Treatment

CASVAC-0401 is a single institution, randomized, open label Phase II/III study, to investigate in CM pts stages IIB, IIC, and III postsurgery (adjuvancy), the efficacy and safety (primary objectives) as well as the quality of life (QOL) and immune response (secondary objectives) of the CSF-470 vaccine vs medium-dose IFN-α2b treatment (ClinicalTrials.gov: NCT01729663). A total of 108 pts will be enrolled in the Phase II–III study. As of March 2016, 47 pts were evaluated, of which 31 were eligible and randomized in a 2:1 ratio (vaccine:IFN-α2b). The randomization scheme was generated by using the Web site Randomization.com (http://www.randomization.com); Nobeltrì S.R.L. (C.R.O.) was responsible for pts randomization. The study was approved by the Ethics Committee of the Instituto Médico Especializado Alexander Fleming (Buenos Aires, Argentina) and by the Argentine Regulatory Agency (ANMAT), and it is being conducted according to the Declaration of Helsinki Principles. All pts signed informed consent.

Vaccine was injected intradermally in the arms or thighs without lymphadenectomy. On day 1, pts received CSF-470 admixed with 1 × 10⁶ colony forming units BCG (Pasteur strain, Instituto Malbrán, Buenos Aires, Argentina) and 100 µg rhGM-CSF (Laboratorio Pablo Cassará, Argentina). On days 2–4, 100 µg rhGM-CSF/day was i.d. injected at the edematous vaccination site. During the 2-year study, pts in the vaccine arm should receive 13 vaccinations: 4 vaccinations 3 weeks apart; 5 vaccinations 2 months apart during the first year and 4 vaccinations 3 months apart during the second year. The pts assigned to the IFN-α2b arm received 10 million units (MU) IFN-α2b (Laboratorio Pablo Cassará, Argentina)/day/5 days a week for 4 weeks; then 5 MU thrice weekly for 23 months (Figure 2).

Patients

Enrollment conditions were as follows: (a) age between 18 and 65 years; (b) CM stages IIB, IIC, or III (AJCC); (c) Performance status Eastern Cooperative Oncology Group (ECOG) 0–1; (d) life expectancy >6 months; (e) no previous chemotherapy or immunotherapy; (f) less than 4 months after surgery; (g) non-evident disease as asserted by CT scans; (h) adequate hematological, hepatic, and renal function; (i) absence of pregnancy, with serum β-HCG determined before each vaccination in premenopausal women; (j) negative serology for HIV, hepatitis B, and hepatitis C. Exclusion criteria were as follows: (a) Type I or II diabetes; (b) pregnancy; (c) morbid obesity; (d) autoimmune diseases...
**FIGURE 1** | Antigenic profile of cutaneous melanoma (CM) cell lines that compose the CSF-470 vaccine as determined by RNAseq (A). Expression of GD2 and GD3 gangliosides in CSF-470 vaccine as determined by flow cytometry (B); isotype-matched immunoglobulins were used as controls to set unspecific labeling.
or hepatitis; (e) chronic medication with corticosteroids or NSAIDs; and (f) psychiatric disorders. More information about the CASVAC-0401 study is presented in File S1 in Supplementary Material.

Assessment of Response and Adverse Events (AEs)
During the study, pts should complete 15 visits; visit 1 was for pt selection and visit 15 for closure participation. Visits 2–14 lasted 4 days for CSF-470 pts and 1 day for IFN-α2b pts. At each visit, after evaluation of laboratory results, pts received a complete clinical examination. Imaging studies were performed as indicated in Figure 2. At baseline (PRE) and after 6 (POST1), 12 (POST2), and 24 months (POST3) of treatment, 200 ml of blood were obtained to monitor immunological parameters (Figure 2). AEs were graded and recorded according to the NCI Common Terminology Criteria for Adverse Events, version 3.0. Clinical evaluation: the end points of the study were DMFS, DFS, OS, toxicity, QOL, and immune response.

Delayed-Type Hypersensitivity (DTH)
On the vaccination day, DTH was performed in the forearm with 1/10th of the CSF-470 dose. The reaction was measured at 1, 24, 48, and 72 h and recorded as follows: 0: macular erythema < 0.5 cm diameter; 1: macular erythema 0.5–1.0 cm; 2: macular erythema 1.1–2.0 cm; 3: macular erythema > 2.0 cm; and 4: papular erythema > 2.0 cm. A DTH score corresponding to the sum of the four values was calculated for each vaccination.

Immune Populations Profile in Peripheral Blood Mononuclear Cells (PBMC) Samples
Peripheral blood mononuclear cells obtained by density gradient were incubated with anti-human MAbs: PerCP-CD3 (clone SK7), FITC-CD4 (clone RPA-T4), FITC-CD8 (clone RPA-T8), FITC-CD20 (clone UCHT1), and APC-CD56 (clone B159) (BD Biosciences, San Jose, CA, USA). For detection of Tregs, 1 × 10⁶ PBMC were stained with mAbs [FITC-CD4, AF647-FoxP3 (clone 259D/C7) and PE-CD25 (clone M-A251) (BD Biosciences)] following the manufacturer’s protocol. Lymphocytes were gated in FSC/SSC dot plot (≥ 30,000 events), and NK (CD3⁻CD56⁺), CD4⁺, CD8⁺, and Tregs (CD4⁺ CD25⁺ FoxP3⁺) cells were determined. Isotype-matched irrelevant Mabs were used as negative controls.

NK cells were tested for degranulating activity (CD107a membrane expression in the CD3⁻CD56⁺ population) by flow cytometry, using canonical K562 cells (ATCC, CCL-243) (38) or MelC (non-irradiated CM cells composing CSF-470 vaccine: MEL-XY1, MEL-XY2, MEL-XY3, and MEL-XX4 cell lines) as targets in a 10:1 ratio as previously described (39). All samples were acquired on a BD FACSCalibur using Cellquest Pro software (BD Biosciences, Franklin Lakes, NJ, USA) and analyzed with FlowJo 7.6.2 software (FlowJo, Ashland, OR, USA).

Frequency of myeloid-derived suppressor cells (CD14⁺CD3⁻CD20⁻CD56⁻HLA-DR⁻) was analyzed by flow cytometry. The following mAbs (BD Biosciences) were used: PE-CD14, FITC-CD3, FITC-CD20, APC-CD56, and PerCP-Cy5.5-HLA-DR (Mouse IgG2a isotype). Data acquisition (≥ 10,000 events) was performed using a FACSCanto II cytometer, using FACS Diva software (BD Biosciences). Data analysis was performed with FlowJo software.

IFN-γ Enzyme-Linked Immunospot Assay (ELISPOT)
PRE and POST1 pts’s PBMC and healthy donor (HD) PBMC were thawed, allowed to rest for 2 h at 37°C and then seeded (1 × 10⁶) in 1 ml of Complete Medium consisting of RPMI 1640 (Invitrogen) supplemented with 10% heat-inactivated human AB sera, 2 mM glutamine, 100 U/mL penicillin, 100 µg/mL streptomycin, 2.5 mM HEPES, and 50 U/mL of IL-2 (Laboratorio Pablo Cassará SRL), in 24-well plates (Costar, Corning, NY, USA). PBMC were stimulated with CSF-470 lysate in a 3:1 ratio (presenting cells from PBMC population: lysed CSF-470 cells), and cultured at 37°C, in 5% CO₂ for 12 days. Every 3 days, fresh complete medium with IL-2 was added. CSF-470 lysate was obtained after five cycles of freezing (liquid nitrogen, 3 min) and thawing (7 min, 37°C) and then centrifuged at 1,000 × g for 10 min to separate nuclei. Lysate aliquots were frozen at −80°C until use.
MultiScreen-IP opaque 96-well plates (High Protein Binding Immobilon-P membrane, Millipore, Bedford, MA, USA) were coated overnight at room temperature with 100 µl/well of 5 µg/ml mouse anti-human IFN-γ mAb (BD Biosciences) in 1X PBS (Gibco, thermo Fisher, USA). Then, the plates were washed and blocked for 2 h at room temperature with 200 µl/well of culture medium consisting of RPMI 1640 (Invitrogen) supplemented with 10% heat-inactivated fetal bovine sera (FBS, Gibco), 2 mM glutamine, 100 U/mL penicillin, 100 µg/ml streptomycin, and 2.5 mM HEPES.

Harvested PBMC from 12-day culture from pts (PRE and POST1 samples) and HD were added to the plates in duplicate at 2.5 × 10^6 cells/well and cultured with either culture medium alone or with addition of OKT3 (30 ng/ml, BD Pharmingen, San Diego, CA, USA) plus PHA (1/1,000, M form, Gibco) for 24 h at 37°C, 5% CO2. The plate was washed twice with deionized water and then thrice with PBS–0.05% Tween-20. A total of 1,000 µl/well of 2 µg/ml anti-human IFN-γ-biotinylated mAb (BD Pharmingen) in 1X PBS/10% FBS were added, and the plates were incubated for 2 h at room temperature. After three washes with PBS–0.05% Tween-20, the plate was incubated with 50 µl/well of streptavidin HRP (BD Pharmingen) diluted 1:100 in PBS 1X/10% FBS for 1 h at room temperature. The plates were then washed four times with PBS–0.05% Tween-20 and then twice with PBS. Spots were visualized by adding 50 µl/well of AEC Substrate (BD Biosciences) for 2 min. Substrate reaction was stopped by washing the plate with deionized water. Plates were scanned using an AID iSPOT ELR0881FL analyzer to quantify the number of spots per well.

**Results**

Patients

The Phase II stage of the CASVAC-0401 study was performed on 31 CM pts who were recruited at the Instituto Alexander Fleming between March 2009 and April 2014. The characteristics and evolution of the participating pts are listed in Table 1, in which it can be seen an equitable distribution of pts in both arms of treatment according to different characteristics between March 2009 and April 2014. The characteristics and evolution of the participating pts are listed in Table 1, in which it can be seen an equitable distribution of pts in both arms of treatment according to different characteristics. However, primary tumor ulceration was more frequent in the vaccine arm. A Consort Flow chart is shown in Figure 3 describing pts demography and treatment assignment. Twenty-one pts (70%) had the BRAFV600E mutation. Pt #030 was withdrawn from protocol after receiving four vaccines due to confirmation that millimetric lung lesions detected by CT-scan at screening, and informed as non-specific, later developed as overt metastases; the pt was, therefore, at stage IV and understaged at screening. This pt was included in the AEi record but excluded from efficacy calculation.

Clinical Response

As of March 2016, pts from CSF-470 vaccine arm received a total of 219 vaccinations (Table 1). A total of 6/19 pts from the vaccine arm and 8/11 pts from the IFN-α2b arm were withdrawn from protocol due to appearance of distant metastases. With a mean and maximum F-UP of 39.4 and 83 months, respectively, DMFS was significantly higher for CSF-470 vaccinated pts than for IFN-α2b pts (p = 0.022). DMFS proportion at 25 months was 72.8% for the
was reduced to 75 μg/day; in only one pt GM-CSF had to be suspended. Fifty milligrams of diphenhydramine were administered p.o. before each vaccination to pts with allergic reactions to prevent symptoms. In the IFN-α2b arm, 3/11 pts interrupted treatment due to excessive toxicity, 5/11 had transitory interruptions and dose reduction and one pt refused to continue treatment within the first month. Only 2/11 pts could complete the 2-year treatment. QOL was significantly better for CSF-470 pts than for IFN-α2b pts as evidenced by both scores obtained from the QOL questionnaire (Figure 4B).

Monitoring of Vaccine-Induced Immune Responses

Delayed-type hypersensitivity skin test increased in every vaccinated pt after receiving CSF-470 (Figure 5A). After seven vaccinations (visit 8), DTH reactivity was higher in pts with no evidence of disease as compared to those with progressive disease (PRO) (Figure 5B). As for PBMC, population frequencies of PRE and POST1 samples were evaluated. In most CSF-470 pts, only CD3−CD56+ NK cells significantly increased after vaccination. NK cells from both PRE and POST1 samples from pts receiving vaccine or IFN-α2b were functionally competent, as detected by in vitro degranulation assays after co-culturing pts’ PBMCs with K562 or MelC as target cells (data not shown). CSF-470 pts had a modest reduction in the CD4+CD25+FoxP3− Treg lymphocyte population, but no changes in CD3+, CD4+ and CD8+ T cell proportions were observed throughout the vaccination. IFN-α2b treated pts showed a significant decrease in CD3+ cell frequency in POST1 samples, particularly in CD4+ and CD8+ T cells (Figure 5C).

Myeloid suppressor (CD14+HLA-DR+) cells were less than 1% of CD14+ cells in PRE and POST1 samples from all pts (data not shown).

In order to determine peripheral blood T cells reactivity to melanoma Ags in both arms of treatment, IFN-γ ELISPOT analysis was performed after stimulation with a vaccine lysate. PRE and POST1 PBMC samples were analyzed (Figure 6). In the vaccine arm, 15/19 pts could be analyzed. Pt #003 was not analyzed due to early recurrence before obtaining the POST1 sample; PBMC from pt #006 could not be expanded in vitro after thawing, pt #011 samples were scarce and in pt #025 blood samples could not be obtained due to bad venous access. In the IFN-α2b arm, 7/11 pts were analyzed. Pt #014, pt #019, pt #027, and pt #028 were not analyzed since their participation in the protocol was discontinued before obtaining the POST1 blood sample. In the vaccine arm, the IFN-γ secreting T cells increased in 14/15 pts and in case of pt #013 they were already high in the PRE sample and in pt #025 they were increased by 75%. In the IFN-α2b arm, in 4/7 pts the number of IFN-γ secreting T cells was low and did not increase with treatment, while in 1/7 they slightly increased. It is remarkable that in pt #002 the number of spots increased with treatment and in pt #024 it was high before treatment and it remained at the same levels at the POST1 sample; both pts remain NED after long

### AEs and QOL

The AEs are listed in Table 2 (CSF-470-vaccinated pts) and Table 3 (IFN-α2b pts). The most common toxicity in CSF-470 pts (20/20) was an inflammatory reaction at the vaccination site, which were grades 1−2 for most pts. Ninety percent of the pts presented mild to moderate pain and 40% had pruritus at the vaccination site. In 6/20 pts, the BCG dose had to be reduced by 75% and pts continued vaccination. Systemic AEs were mild (grade 1); one pt with gastritis required treatment with omeprazole and ranitidine and symptoms resolved within 24 h. A total of 4/20 pts presented allergic reactions, mainly cutaneous rash, pruritus, and dyspnea (grades 2−3). In these pts, GM-CSF dose

### Table 2: Characteristics of patients (pts) participating in the CASVAC-0401 study.

| Characteristics | Treatment arm |  |
|-----------------|---------------|--|
|                 | CSF-470 | IFN-α2b |
| **n**           | 20      | 11      |
| **Sex**         |         |         |
| Male            | 12 (60.0%) | 5 (45.5%) |
| Female          | 8 (40.0%)  | 6 (54.5%) |
| **Age** (median, range) | 46.0 (33–61) | 53.0 (29–64) |
| **AJCC-UICC melanoma staging** |         |         |
| II              | 2 (10.5%) | 0 (0%)   |
| IIIB            | 8/17 (47.1%) | 2/11 (18.2%) |
| IIIC            | 4/17 (23.6%) | 4/11 (36.4%) |
| (Tx)           | 2/17 (11.7%) | 2/11 (18.2%) |
| **Primary tumors** |         |         |
| Breslow thickness (median, range) | 3.2 (0.89–5.5) | 3.0 (0.6–15.0) |
| Ulceration      | 12/17 (70.6%) | 3/11 (27.3%) |
| **Treatment**   |         |         |
| Number of vaccine doses received | 13 (65.0%) | 13 (65.0%) |
| 1               | 12 (60.0%) | 12 (60.0%) |
| 2               | 1 (5.0%)  | 1 (5.0%)  |
| 3               | 1 (5.0%)  | 1 (5.0%)  |
| 4               | 1 (5.0%)  | 1 (5.0%)  |
| **No significant differences among CSF-470 and IFN-α2b arms were found regarding sex (χ² test, p = 0.4362); age (unpaired t-test with Welch’s correction, p = 0.6550). AJCC-UICC staging (II vs III, χ² test, p = 0.2905); IIIA vs IIIB, IIIC, χ² test, p = 0.3263). Breslow thickness (unpaired t-test with Welch’s correction, p = 0.3253) or ulceration of primary tumors (χ² test, p = 0.6550). TX, unknown primary tumor.** |
F-UP. In the IFN-α2b arm, the difference between the PRE and POST1 samples was not statistically significant (Figure 6).

Thus, there are pts in both arms who recognize Ags contained in CSF-470 vaccine even before any treatment and vaccination induces a significant increase in T cell response.

All vaccinated pts significantly increased their serum Abs reactivity against MelC (PRE vs POST1 samples) (Figure 7A). In the case of pt #006, increased serum reactivity against autologous tumor cells derived from a s.c. metastasis was detected (Figure 7B); the Abs title returned to the PRE level 2-year after ending her participation in the study (2-year F-UP sample). Particularly, tumor cell surface reactivity was evident in the POST1 sample (Figure 7C).

DISCUSSION

The adjuvant treatment of stages IIB, IIC, and III CM pts after surgery is a challenging issue. Whereas some untreated pts may remain without recurrence for years, others will relapse within weeks or months. At present, there is no way to differentiate both groups except for risk factors, since present technology is not sensitive enough to detect micrometastatic foci. Since about 30–50% of such pts, according to the disease stage, remain “relapse-free” after surgery without any treatment (43), an equilibrium between effectiveness and lack of toxicity for adjuvant therapy must be found. The main results of the Phase II CASVAC-0401 study are that after a mean F-UP of more than 3 years, 13/19 vaccinated pts (68.4%) remained free of distant metastases, although three of them developed loco-regional s.c. metastases that were removed as permitted by protocol (pts #004, #005, #025). On the contrary, only 3/11 IFN-α2b-treated pts (27%) remained free of distant metastases. The fact that DMFS, but not yet DFS, was statistically higher in the CSF-470 arm than in the IFN-α2b arm is biologically meaningful since it has been shown that pts with resectable loco-regional metastases remain at low risk of further progression (44). Also, the administration of CSF-470 vaccine plus BCG plus rhGM-CSF was safe and well tolerated; it was associated with a better QOL than IFN-α2b treatment. The observed AEs were similar to those reported in a previous Phase I study (29) and were mostly related to local reaction.

As to the mechanism of action, we suggest that CSF-470 plus BCG plus rhGM-CSF triggered both innate and adaptive immunities. CSF-470 is a mixture of four CM cell lines which are heterogeneous for HLA class I haplotype and for expression of melanoma associated Ags (30). With respect to induction of adaptive immunity, we suggest the following mechanism: the danger signals provided by allogeneic HLAs and adjuvants BCG...
and GM-CSF would force attraction of Ag-presenting cells (DCs and macrophages) to the vaccination site, where they would phagocyte tumor Ags (26) and present them in an adequate HLA setting to naïve lymphocytes, either in situ or upon migration to draining lymph nodes (45, 46).

As we have shown in this paper, each cell line displays a characteristic set of shared Ags, and their combination offers the immune system a wide variety of melanoma differentiation Ags, cancer-testis Ags, and gangliosides. We have demonstrated by ELISPOT analysis that CSF-470-vaccinated pts develop strong T cell reactivity against a vaccine lysate. This result suggests that a considerable amount of vaccinated pts’s PBMC are reacting against melanoma Ags contained in the vaccine. The nature of the recognized Ags deserves further analysis. However, it is worth mentioning that
**TABLE 2 | AEs in CSF-470-vaccinated patients.**

| AE                               | Patients with AE | Intensity |
|----------------------------------|------------------|-----------|
|                                 | Grade 1 | Grade 2 | Grade 3 | Grade 4 |
| Inflammatory reaction at vaccine site | 20     | 0       | 20      | 0       |
| Pain at vaccine site             | 18     | 18      | 0       | 0       |
| Asthenia                         | 16     | 16      | 0       | 0       |
| Headache                         | 14     | 12      | 2       | 0       |
| Myalgia                          | 9      | 9       | 0       | 0       |
| Pruritus at vaccine site         | 8      | 8       | 0       | 0       |
| Abdominal pain                   | 7      | 7       | 0       | 0       |
| Diarrhea                         | 6      | 6       | 0       | 0       |
| Lumbar pain                      | 6      | 6       | 0       | 0       |
| Allergic reaction                | 4      | 0       | 1       | 3       |
| Fever                            | 4      | 4       | 0       | 0       |
| Gastritis                        | 4      | 3       | 1       | 0       |
| Arthritic pain                   | 3      | 3       | 0       | 0       |
| Fatigue                          | 3      | 3       | 0       | 0       |
| Hypotension                      | 3      | 3       | 0       | 0       |
| Nausea                           | 3      | 3       | 0       | 0       |
| Chills                           | 2      | 2       | 0       | 0       |
| Cramps                           | 2      | 2       | 0       | 0       |
| Preocordial pain                 | 2      | 2       | 0       | 0       |
| Vomits                           | 2      | 2       | 0       | 0       |
| Anorexia                         | 1      | 1       | 0       | 0       |
| Hematopspermia                   | 1      | 1       | 0       | 0       |

AE, adverse event.

Total patients receiving at least one dose of vaccine: n = 20.

some pts in both arms had reactivity against CSF-470 Ags even before treatment. Those pts are long-term survivors, and this suggests that the CSF-470 vaccine is a carrier of relevant Ags and that, if detected before any treatment starts, might be a marker of good prognosis. In most vaccinated pts, the IFN-γ secreting cells increased, demonstrating that this vaccination system induces a Th1 response. The fact that PRE vaccination T cells could be stimulated to secrete IFN-γ upon incubation with CSF-470 lysate implies that an immune response probably directed to common melanoma Ags present in the vaccine cells has been elicited.

Coincidently, we have also observed in this study significant increases in DTH and humoral responses (serum Abs) after CSF-470 vaccination; and it has been extensively demonstrated that DTH is useful to evaluate cellular immune responses (47, 48).

With respect to the innate immunity response, we have observed a significant increase in functional NK cells in PBMC from CSF-470 pts after the sixth vaccination (6 months of treatment), and we suggest that NK cells exert killing of tumor cells that have lost HLA-I expression (49, 50). It is important to note that in 6/14 vaccinated pts amenable to analysis, less than 50% of tumor cells retained HLA expression and that in some pts HLA expression decreased from primary tumors to metastases (Table S1 in Supplementary Material). These findings could lead us to postulate that development of innate immunity may have contributed to the more favorable course of vaccinated pts. Such hypothesis is supported by the experimental work of Malladi et al., who found that ablation of NK cells dramatically increased the ability of latency competent cells to survive and metastasize (51). Since we also observed an increment in serum Abs recognizing autologous tumor cells (pt #006), it may also be suggested that the strong Ab response mediates Ab-dependent cellular cytotoxicity targeting either circulating tumor cells and/or micrometastatic foci.

GM-CSF containing vaccines were previously shown to expand a population of CD14+HLA-DR− myeloid cells endowed with a TGF-β-mediated immune suppressive activity at short intervals near vaccine and GM-CSF administration, revealing an immune suppression activity modulated by GM-CSF-based autologous vaccine, as reported by Filipazzi et al. (52). However, we only detected minimal numbers of circulating myeloid suppressor cells either before (PRE) or after 6 months treatment (POST1). Since samples were obtained at fixed times as established by the protocol, our data may not be comparable our results to those previously reported.
FIGURE 5
Continued

A

Visit

DTH score

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

B

After 7th vaccine

DTH score

PRO NED

C

Lymphocytes

NK cells

CD4 cells

CD8 cells

SSC

FSC

CD3

CD3

CD3

Tregs

CD25

FoxP3

%NK

%Tregs

%CD3

%CD4

%CD8

CSF-470

IFN-γ2b

PRE POST1

PRE POST1

PRE POST1

PRE POST1

PRE POST1

PRE POST1

PRE POST1

PRE POST1

PÆF POST1

PÆF POST1

PÆF POST1

PÆF POST1

PÆF POST1
Immune checkpoint blockade has the capacity to enhance and sustain endogenous immunity against non-mutated tumor-associated Ags as well as uniquely mutated Ags, establishing durable tumor control (53). After anti-CTLA-4 treatment, evidence of an immune response targeting tumor neoepitopes provided a genetic basis for anti-immune checkpoint response. Mutational load was associated with the degree of clinical benefit, and a neoantigen landscape is specifically present in tumors with a strong response to CTLA-4 blockade. Predicted neoantigens were able to activate T cells from the pts treated with ipilimumab in vitro (54). Also, inhibition of PD1/PD-L1 pathway was shown to influence the evolving landscape of tumor neoantigens during the emergence of acquired resistance to treatment, involving genetic changes in the tumor to eliminate such neoantigens (55). Given the safety and good tolerance of CSF-470 vaccine and the results obtained so far in this Phase II study, it would be interesting to test if addition of immune checkpoint inhibitors to CSF-470 vaccination could result in better stimulation of immune responses and higher clinical benefit to high risk CM pts in a future study.

Expressed somatic mutations present in the CSF-470 vaccine will be identified after whole exome sequencing of the CM cell lines; in silico epitope prediction will be performed and epitope-specific peptides will be selected to analyze their immune recognition by vaccinated pt’s T cells, considering their HLA restriction. Also, melanoma biopsies from some pts will be equally analyzed in the near future to investigate the epitope spreading hypothesis after CSF-470 vaccination.

To summarize, the CSF-470 vaccine plus BCG plus rhGM-CSF administered as adjuvant therapy to stages IIB, IIC, and III CM pts was superior to IFN-α2b treatment in delaying or preventing
progression to distant metastasis; it was well tolerated and it was associated with an improved QOL. These results encourage the continuation of a Phase III part of the CASVAC-0401 study.

**ETHICS STATEMENT**

This study was carried out in accordance with the recommendations of the “Ethics Committee of the Instituto Médico Especializado Alexander Fleming” with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the “Ethics Committee of the Instituto Médico Especializado Alexander Fleming (Buenos Aires, Argentina)” and by the local Regulatory Agency (ANMAT - Argentina).” The “Ethics Committee of the Instituto Médico Especializado Alexander Fleming (Buenos Aires, Argentina)” is reputed by the Central Ethics Committee of the City of Buenos Aires (Argentina).

**AUTHOR CONTRIBUTIONS**

JM: conception and design of the study; collection and assembly of data; data analysis and interpretation; and manuscript writing.
J M was the principal investigator of the study. MP, MA, and PB: collection and assembly of data; data analysis and interpretation; and manuscript writing. ML: conception and design of the study; data analysis and interpretation; and manuscript writing. SM, MC, AB, AO, FR, EE, EL, and MB: data analysis and interpretation; manuscript writing. JO: collection and assembly of data; data analysis and interpretation; and manuscript writing.

ACKNOWLEDGMENTS

We dedicate this work to our patients. We thank the Departments of Hemotherapy, Pathology, Microbiology, Library, and Pharmacy from Instituto Médico Especializado Alexander Fleming for their help in this study.

REFERENCES

1. Aris M, Barrio MM, Mordoh J. Lessons from cancer immunoediting in cutaneous melanoma. Clin Dev Immunol (2012) 2012:1929719. doi:10.1155/2012/1929719
2. Schumacher TN, Schreiber RD. Neantigenic in cancer immunotherapy. Science (2015) 348:689–74. doi:10.1126/science.aac9711
3. Shain AH, Yeh I, Kovalyshyn I, Tsalikian A, Talevich E, Gagnon A, et al. The genetic evolution of melanoma from precursor lesions. N Engl J Med (2015) 373:1926–36. doi:10.1056/NEJMoa1502583
4. Finning J, Rubinstein A, Hammerbacher J, Bhardwaj N. Mutation-derived tumor antigens: novel targets in cancer immunotherapy. Oncology (Williston Park) (2015) 29:970–5.
5. Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 14:73. doi:10.1186/s12916-016-0623-5
6. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369:122–33. doi:10.1056/NEJMoa1302369
7. Chang C-C, Pirozzi G, Wen S-H, Chung I-H, Chiu B-L, Errico S, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol (2013) 31:1152–8. doi:10.1038/nbt.2934
8. Kirkwood JM, Bender C, Agarwala S, Tarhini A, Smelko B, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol (2002) 20:3703–18. doi:10.1200/JCO.2002.03.052
9. Eggermont AMM, Suciu S, Testori A, Santinami M, Kruit WHJ, Marsden J, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol (2015) 16:522–30. doi:10.1016/S1470-2045(15)01221-1
10. Grossmann KE, Othus M, Tarhini AA, Patel SP, Moon J, Sondak VK, et al. e12032-SWOG S1404: a phase III randomized trial comparing standard of care adjuvant therapy to pembrolizumab in patients with high risk resected melanoma. J Clin Oncol (2016) 34(Suppl):abstr21032.
11. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 364:2119–27. doi:10.1056/NEJMoa1101283
12. Wada S, Jackson CM, Yoshimura K, Yen H-R, Getnet D, Harris TJ, et al. Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med (2013) 11:89. doi:10.1186/1479-5876-11-89
13. Lotem M, Merims S, Frank S, Hamburger T, Nissen A, Kadouri L, et al. Adjuvant autologous melanoma vaccine for macroscopic stage III disease: survival, biomarkers, and improved response to CTLA-4 blockade. J Immunol Res (2016) 2016:1–12. doi:10.1155/2016/8121985
14. Aris M, Zubieta MR, Colombo M, Arriaga JM, Bianchini M, Alperovich M, et al. MART-1- and gp100-expressing and non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro. J Invest Dermatol (2012) 132:365–74. doi:10.1038/jid.2011.312
15. Brandau S, Riemsenberger J, Jacobsen M, Kemp D, Zhao W, Zhao X, et al. NK cells are essential for effective BCG immunotherapy. Int J Cancer (2001) 92:697–702. doi:10.1002/1097-0215(20010601)92:5<697::AID-IJC225>3.0.CO;2-Z
16. Kleinnijenhuis J, Quentin J, Preijers F, Joosten LA, Jacobs C, Xavier RJ, et al. BCG-induced trained immunity in NK cells: role for non-specific protection to infection. Clin Immunol (2014) 155:213–9. doi:10.1016/j.clim.2014.10.005
17. Parolini C, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol (2007) 18:226–32. doi:10.1093/annonc/mdl158
18. Vogel DYS, Kooij G, Heijnen PDAM, Breur M, Peferoen LAN, van der Valk P, et al. GM-CSF promotes migration of human monocytes across the blood brain barrier. Eur J Immunol (2015) 45:1808–19. doi:10.1002/eji.201444960
19. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature (2007) 449:419–26. doi:10.1038/nature06175
20. Aris M, Bravo AI, Barrio MM, Mordoh J. Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report. Front Immunol (2015) 6:144. doi:10.3389/fimmu.2015.00144
21. Pizzurro GA, Tapia IJ, Sganga L, Podhajcer OL, Mordoh J, Barrio MM. Cytokine-enhanced maturation and migration to the lymph nodes of a human dying melanoma cell-loaded dendritic cell vaccine. Cancer Immunol Immunother (2015) 64:1393–406. doi:10.1007/s00262-015-1743-z

FUNDING

This work was supported by grants from CONICET, Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT), Instituto Nacional del Cáncer—Ministerio de Salud de la Nación Argentina (INC-MSal), Fundación Sales, Fundación Cáncer, Fundación Pedro F. Mosoteuy, Argentina. The study was sponsored by Laboratorio Pablo Cassará S.R.L.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fimmu.2017.00625/full#supplementary-material.
